This phase III trial is evaluating the safety and effectiveness of two targeted therapies, compared to chemotherapy, for the treatment of non-small cell lung cancer that has spread to other parts of the body and has gotten worse on prior treatment .
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy
Eligible patients will be randomised to receive oral lenvantinib as a monotherapy or in combination with intravenous pembrolizumab, or intravenous docetaxel alone until disease progression or unacceptable toxicity.
Recruiting Hospitals Read More